Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of -33.33% and -100.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that the independent Data Safety Monitoring Board (DSMB) for the EnACT study has completed its planned review of initial safety and tolerability data from the Part 1 dose escalation phase and unanimously approved proceeding with enrollment in the Part 2 efficacy phase at 2g of MAT2203 daily, the highest dose tested in Part 1. The 2g dose will be tested in the 2-week induction phase of treatment. Part 2 of the EnACT study will explore the use of MAT2203 for both induction and maintenance therapy in HIV-patients with cryptococcal meningitis, a life-threatening fungal infection most commonly observed in immunocompromised individuals.

Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Monday, March 9, 2020 at 8:00 a.m. ET to discuss operational and financial results for the fourth quarter and full year ended December 31, 2019. Matinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions.

As of late, it has definitely been a great time to be an investor of Matinas BioPharma

Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to participate in a panel discussion, as well as host investor meetings, during the Maxim Group Infectious Disease Virtual Conference. Investors interested in arranging a virtual meeting with the Company's management during this conference should contact the conference coordinator, Soraya Dorce (sdorce@maximgrp.com). A live audio webcast of the panel discussion will be available on the Events page of the Investors section of the Company’s website (www.matinasbiopharma.com) and at M-Vest.

Every investor on earth makes bad calls sometimes. But really bad investments should be rare. So take a moment to...

The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) gained about 6% for the week.Large-cap pharma names AstraZeneca plc (NYSE: AZN) a…

– ENHANCE-IT study of MAT9001 against Vascepa® set to resume in June 2020 – – EnACT study of MAT2203 in cryptococcal meningitis expected to resume in June 2020 – – Management.

Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a company overview during the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 8:00 a.m. ET. Investors interested in arranging a virtual meeting with the Company's management during this conference should contact the conference coordinator. A live webcast of the panel discussion will be available on the IR Calendar page of the Investors  section of the Company’s website (www.matinasbiopharma.com).

Whilst it may not be a huge deal, we thought it was good to see that the Matinas BioPharma Holdings, Inc...

Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Monday, May 11, 2020 at 4:30 p.m. ET to discuss operational and financial results for the first quarter ended March 31, 2020. Matinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions.

Matinas Biopharma Holdings Inc (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that it has initiated the ENHANCE-IT Study (Pharmacodynamic Effects of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids to ENHANCE Efficacy in Adults with Hypertriglyceridemia), a head-to-head pharmacodynamic (PD) study of MAT9001 against Vascepa® in patients with elevated triglycerides (150-499 mg/dL). The ENHANCE-IT study will assess MAT9001’s effectiveness in reducing triglyceride levels and other important lipid markers, as well as gather important data on bioavailability and blood levels of eicosapentaenoic acid (EPA) and other omega-3 fatty acids. “The ENHANCE-IT study is a significant next step in our clinical development program designed to highlight the impressive efficacy of MAT9001 and further distinguish its superior profile from Vascepa,” commented James J. Ferguson, M.D., Chief Medical Officer of Matinas.

Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.The week was light on news flow, barring some smid-cap earnings and COVID-19 treatment and vaccine news. View more earnings on IBBThe following are key catalysts in the unfolding week that a biotech investor should stay tuned to. Conferences Barclays Global Healthcare Conference: March 10-12 in Miami, Florida. American Academy of Allergy Asthma and Immunology, or AAAAI, Annual Meeting: March 13-16 in Philadelphia, Pennsylvania.PDUFA Dates The FDA is set to rule on Bristol-Myers Squibb Co's (NYSE: BMY) sBLA for Opdivo \+ Yervoy as a treatment option for patients with advanced hepatocellular carcinoma who were previously treated with Bayer AG (OTC: BAYRY) and Onyx Pharma's Nexavar. The PDUFA date has been set for Tuesday.Clinical Readouts Blueprint Medicines Corp (NASDAQ: BPMC) is scheduled to present at the AAAAI annual meeting with Phase 2 data for Avapritinib, which is being evaluated for treating indolent and smoldering systemic mastocytosis.See also: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates Earnings Monday * Matinas BioPharma Holdings Inc (NYSE: MTNB) (before the market open) * Minerva Neurosciences Inc (NASDAQ: NERV) (before the market open) * BioXcel Therapeutics Inc (NASDAQ: BTAI) (before the market open) * Assertio Therapeutics Inc (NASDAQ: ASRT) (after the close) * SI-Bone Inc (NASDAQ: SIBN) (after the close) * Xenon Pharmaceuticals Inc (NASDAQ: XENE) (after the close) * Organogenesis Holdings Inc (NASDAQ: ORGO) (after the close) * Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) (after the close)Tuesday * Precision BioSciences Inc (NASDAQ: DTIL) (time not provided) * Akebia Therapeutics Inc (NASDAQ: AKBA) (before the market open) * Catabasis Pharmaceuticals Inc (NASDAQ: CATB) (before the market open) * InspireMD Inc (NYSE: NSPR) (before the market open) * ChemoCentryx Inc (NASDAQ: CCXI) (after the close) * CV Sciences Inc (OTC: CVSI) (after the close) * Fulgent Genetics Inc (NASDAQ: FLGT) (after the close) * Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) (after the close) * RA Medical Systems Inc (NYSE: RMED) (after the close) * Protagonist Therapeutics Inc (NASDAQ: PTGX) (after the close)Wednesday * Xeris Pharmaceuticals Inc (NASDAQ: XERS) (before the market open) * Liquidia Technologies Inc (NASDAQ: LQDA) (before the market open) * Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) (before the market open) * INmune Bio Inc (NASDAQ: INMB) (before the market open) * Clearside Biomedical Inc (NASDAQ: CLSD) (after the close) * Calithera Biosciences Inc (NASDAQ: CALA) (after the close) * Unity Biotechnology Inc (NASDAQ: UBX) (after the close) * Navidea Biopharmaceuticals Inc (NYSE: NAVB) (after the close) * Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) (after the close) * BioLife Solutions Inc (NASDAQ: BLFS) (after the close) * Dynavax Technologies Corporation (NASDAQ: DVAX) (after the close) * Miragen Therapeutics Inc (NASDAQ: MGEN) (after the close) * Pfenex Inc (NYSE: PFNX) (after the close) * Thursday * Aquestive Therapeutics Inc (NASDAQ: AQST) (before the market open) * Avadel Pharmaceuticals PLC (NASDAQ: AVDL) (before the market open) * Axsome Therapeutics Inc (NASDAQ: AXSM) (before the market open) * Aldeyra Therapeutics Inc (NASDAQ: ALDX) (before the market open) * Selecta Biosciences Inc (NASDAQ: SELB) (before the market open) * Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) (before the market open) * Provention Bio Inc (NASDAQ: PRVB) (before the market open) * Protalix Biotherapeutics Inc (NYSE: PLX) (before the market open) * Evofem Biosciences Inc (NASDAQ: EVFM) (before the market open) * China Biologic Products Holdings Inc (NASDAQ: CBPO) (before the market open) * Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) (before the market open) * Pieris Pharmaceuticals Inc (NASDAQ: PIRS) (before the market open) * X4 Pharmaceuticals Inc (NASDAQ: XFOR) (before the market open) * Polarityte Inc (NASDAQ: PTE) (before the market open) * Rubius Therapeutics Inc (NASDAQ: RUBY) (before the market open) * Agenus Inc (NASDAQ: AGEN) (before the market open) * ADMA Biologics Inc (NASDAQ: ADMA) (after the close) * BioDelivery Sciences International, Inc. (NASDAQ: BDSI) (after the close) * Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) (after the close) * Celcuity Inc (NASDAQ: CELC) (after the close) * Lineage Cell Therapeutics Inc (NYSE: LCTX) (after the close) * Chembio Diagnostics Inc (NASDAQ: CEMI) (after the close) * Harpoon Therapeutics Inc (NASDAQ: HARP) (after the close) * Flexion Therapeutics Inc (NASDAQ: FLXN) (after the close) * Neoleukin Therapeutics Inc (NASDAQ: NLTX) (after the close) * Rockwell Medical Inc (NASDAQ: RMTI) (after the close) * Inovio Pharmaceuticals Inc (NASDAQ: INO) (after the close) * Savara Inc (NASDAQ: SVRA) (after the close) * Ocular Therapeutix Inc (NASDAQ: OCUL) (after the close) * Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) (after the close)Friday * PLx Pharma Inc (NASDAQ: PLXP) (before the market open) * Achieve Life Sciences Inc (NASDAQ: ACHV) (before the market open)IPOs Imara, a biopharma company that is developing therapies for rare hemoglobinopathies, has filed to offer 4.45 million shares in an IPO, to be priced between $16 and $18. The company seeks to list its shares on the Nasdaq under the ticker symbol "IMRA."IPO Quiet Period Expiry Revolution Medicines Inc (NASDAQ: RVMD)Related Link: How The COVID-19 Outbreak Is Benefiting Biotech Investors See more from Benzinga * The Daily Biotech Pulse: Breakthrough Device Designation For Neuronetics, AbbVie Receives European Label Expansion, AstraZeneca Flunks Late-Stage Study * The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19 * The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Q4 2019 Matinas BioPharma Holdings Inc Earnings Call

Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB) today announced the appointment of James A. Underberg, M.D., M.S., FACPM, FACP, FNYAM, FASPC, FNLA to its Scientific Advisory Board (SAB). Dr. Underberg is a Clinical Assistant Professor of Medicine at NYU School of Medicine and the NYU Center for Prevention of Cardiovascular Disease.

NEW YORK, NY / ACCESSWIRE / March 9, 2020 / Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March ...

Penny stocks, you either love them or you hate them. One of the obvious draws of these stocks trading for under $5 per share is the ability to get more bang for your buck. And should these bargain priced stocks see their share prices rise by only a small amount, the rewards can be staggering.However, before jumping right into an investment in a penny stock, Wall Street pros advise looking at the bigger picture and considering other factors beyond just the price tag. For some names that fall into this category, you really do get what you pay for, offering little in the way of long-term growth prospects thanks to weak fundamentals, recent headwinds or even large outstanding share counts.Taking all of this into consideration, we used TipRanks’ Stock Screener tool to zero in on the crème-de-la-crème when it comes to penny stocks. We are referring to the names that have not only received substantial support from Wall Street analysts but also boast sky-high upside potential from their current levels. Let's take a closer look.Matinas BioPharma Holdings (MTNB) Through the development of its lead candidate, MAT9001, Matinas BioPharma wants to offer new treatments for cardiovascular and metabolic conditions. MAT9001 is an omega-3 fatty acid-based drug designed as a more effective hypertriglyceridemia treatment. With it well positioned in an expanding market, SunTrust Robinson analyst Gregg Gilbert believes that at $1.35 per share, now is the time to buy.Despite having struggled year-to-date, investors shouldn’t panic according to the analyst. MTNB’s descent was partly related to the early success of its competitor Amarin’s Vascepa, its omega-3 fatty acid drug, as its label expansion to include cardiovascular risk reduction was just approved in December. However, Gilbert actually sees Vascepa’s launch as a positive for MTNB.Gilbert cites the growth of the omega-3 class as the source of his optimism. Currently, there are only two prescription omega-3s to reduce triglycerides in patients with severe hypertriglyceridemia available in the U.S., Lovaza and Vascepa. As more and more research is conducted, the evidence in support of the benefits of omega-3s is mounting, implying that there’s plenty of room for MTNB to take market share.On top of this, Gilbert points out that MAT9001 is unique in that it contains EPA and DPA in free fatty acid form and is highly bioavailable. Based on early clinical data, the drug’s composition has been shown to produce substantial reductions in lipid markers and higher bioavailability compared to Vascepa. “While a few years from market, we believe MAT9001 could carve out a nice slice of the omega-3 market given its unique characteristics,” the analyst commented.While noting that it’s difficult to gauge the size of the omega-3 market, about 4 million patients are candidates for Lovaza or Vascepa based on the indication for severe hypertriglyceridemia. With the recent expansion of Vascepa’s label, the opportunity could be further expanded.All of the above prompted Gilbert to kick off his MTNB coverage by issuing a bullish call. At his $3 price target, shares could be in for a 122% gain over the next twelve months. (To watch Gilbert’s track record, click here)What does the rest of the Street think? As it turns out, all 5 of the analysts that have published a recent review see the stock as a Buy, making the consensus rating a unanimous Strong Buy. Adding to the good news, the $3.30 average price target indicates 144% upside potential. (See Matinas BioPharma price targets and analyst ratings on TipRanks)Marrone Bio Innovations (MBII) For Marrone Bio, sustainability is the name of the game. The company uses microorganisms isolated from samples collected from flowers, insects, soil and composts to find effective solutions for pest management and plant health. Currently trading for $1.14 per share, some argue that this price can only go up from here.During the first three quarters of 2019, the company was able to report revenue growth of 46% year-to-date. However, its disappointing bottom line results have worried investors. Even with the revenue gains, earnings haven’t improved. That being said, National Securities analyst Ben Klieve thinks that MBII’s financials are in for a change. He cites its investments in several growth initiatives as potentially fueling reductions in adjusted EBITDA losses.Additionally, Klieve highlights the improvements in both gross margins and gross profit and new collaborations with Corteva and Compass Minerals as being encouraging signs. “We believe this momentum can continue into the fourth quarter and carry into 2020. With organic growth being supplemented by the acquisition of Pro Farm, we expect revenue growth can again approach 50% in 2020 with continued progress in gross margins,” he explained.Based on the company’s efforts to drive a turnaround, Klieve kept both his Buy rating and $2.50 price target as is. This implies that shares could climb 119% higher in the next twelve months. (To watch Klieve’s track record, click here)Meanwhile, Amit Dayal of H.C. Wainwright points to the EPA’s recent approval of two of its biofungicide products, Stargus and Regalia, for use on hemp plants as reaffirming his bullish thesis. Since 2018, no other crop protection products have been given the thumbs up for use on hemp. Not to mention the company estimates the hemp market in 2018 reached over $1.1 billion and could more than double by 2022.“We believe that being the first company with EPA approved crop protection products for use in hemp–in addition to these products being bio-based–affords Marrone a significant competitive advantage,” Dayal commented. Thanks to this development, the analyst reiterated his bullish call. At $2.50, his price target mirrors Klieve’s. (To watch Dayal’s track record, click here)When it comes to other analyst activity, it has been relatively quiet on Wall Street. The two analysts above have published the only recent reviews, making the consensus rating a Moderate Buy. (See Marrone Bio stock analysis on TipRanks)TETRA Technologies (TTI)Switching gears now, TETRA provides the upstream energy industry with solutions for completion fluids and water management as well as offers various compression services. According to one analyst, its price tag of $1.51 a share is a steal.B.Riley FBR’s Tom Curran does acknowledge that its onshore NAM OFS businesses, especially water and flowback's services in the Permian, continue to face challenges, and its long-term hydrochloric acid (HCI) supply agreement impacts the value of its mechanical evaporation (ME) plant in the near-term. Having said that, he argues TTI has a lot going for it. During a recent conference, management stated that the operator who awarded it the CS Neptune project should have started completions activity during Q4 2019, beginning the consumption of product under the contract.Curran argues that this would be a huge step forward, writing, “Although there is a real possibility that the completion phase did not start until later in 4Q19 and could spill over into 1Q20, we believe that the mere commencement of Neptune sales under this contract should be a significant positive for both TTI's stock sentiment and fundamental story, especially since the product is so lucrative that even a modest amount of revenue recognition should have a pronounced impact on the division's margin.”He concluded by noting, “We continue to like TTI's cheap valuation, which we suspect is partly due to misperceptions about TTI-only's actual debt burden; Completion Fluids division's promising CS Neptune product suite and structurally increasing profitability; and Water & Flowback division's potential to significantly rebound as competitive improvements converge with a cyclical upswing.”To this end, Curran maintained a Buy recommendation. Despite reducing the price target from $3.75 to $3.50, he still believes a 132% twelve-month gain could be in store. (To watch Curran’s track record, click here)Looking at the consensus breakdown, only one other analyst has thrown an opinion into the mix. However, the rating was also bullish, making the Street consensus a Moderate Buy. While lower than Curran’s forecast, the $2.88 average price target still suggests huge upside potential of 91%. (See TETRA stock analysis on TipRanks)

Initiated ENHANCE-IT study of MAT9001 against Vascepa®. Topline data expected Q4 2020 Initiated efficacy phase of NIH-funded EnACT study of MAT2203 in cryptococcal meningitis.

Q1 2020 Matinas BioPharma Holdings Inc Earnings Call

Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today commented on the recent United States District Court decision to invalidate patents related to Amarin Corporation’s Vascepa and also provided an update on the effect of the rapidly evolving COVID-19 pandemic on its business operations and clinical development programs. Matinas is aware of the United States District Court for the District of Nevada’s ruling yesterday in favor of the generic companies in Amarin Corporation’s patent litigation against two filers of abbreviated new drug applications, or ANDAs, for Amarin’s Vascepa.